Clinical Edge Journal Scan

Degree of disease control influences abnormalities in renal parameters in PsA


 

Key clinical point: The association between abnormalities in renal function parameters and disease activity may be guided by the degree of disease control in psoriatic arthritis (PsA), with disease relapse having a significant effect on renal function in patients with PsA.

Major finding: Renal dysfunction was experienced by 38.5%-58.3% of patients with PsA within 12 months of treatment initiation. Patients with vs. without disease relapse had significantly higher mean serum creatinine levels ( P = .031) at treatment initiation; however, clinical remission or treatment type did not seem to affect renal function parameters.

Study details: This single-center retrospective study included 45 patients with PsA (n = 23) or rheumatoid arthritis (n = 22) who received appropriate medication and underwent renal function evaluation every 3-6 months.

Disclosures: This study was supported by Novartis. The authors declared no conflict of interests.

Source: Atzeni F et al. Frequency of renal function parameter abnormalities in patients with psoriatic arthritis and rheumatoid arthritis: Real-world evidence from clinical practice. J Clin Med. 2022;11(4):1029 (Feb 16). Doi: 10.3390/jcm11041029

Recommended Reading

Drug survival study looks at what lasts longest in RA, axSpA, PsA, and psoriasis
MDedge Rheumatology
CV risk biomarkers tentatively identified in psoriatic disease
MDedge Rheumatology
Study links air pollution to psoriasis flares
MDedge Rheumatology
Trial gives new guidance for choosing initial PsA treatment
MDedge Rheumatology
Introducing adalimumab vs. escalating methotrexate in patients with inadequately controlled PsA
MDedge Rheumatology
PsA: Methotrexate+leflunomide more effective but less well tolerated than methotrexate monotherapy
MDedge Rheumatology
PsA: Comparable efficacy, safety, and persistence with TNFi or ustekinumab in real world
MDedge Rheumatology
Reduced humoral response to SARS-CoV-2 vaccine in patients receiving systemic therapy for PsA
MDedge Rheumatology
Scoring by MRI is an effective way to identify change in clinical outcomes of PsA
MDedge Rheumatology
PsA: Deucravacitinib shows promise in phase 2
MDedge Rheumatology